Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development	$ 268,823	$ 285,885	$ 248,626
Research and development related success payments and contingent consideration	(48,981)	(84,882)	57,873
General and administrative	73,299	71,561	50,410
Total operating expenses	293,141	272,564	356,909
Loss from operations	(293,141)	(272,564)	(356,909)
Interest income, net	9,938	3,762	676
Other income (expense), net	(52)	(674)	305
Net loss	$ (283,255)	$ (269,476)	$ (355,928)
Net loss per common share - basic	$ (1.46)	$ (1.43)	$ (2.14)
Net loss per common share - diluted	$ (1.46)	$ (1.43)	$ (2.14)
Weighted-average number of common shares - basic	194,541	188,344	166,433
Weighted-average number of common shares - diluted	194,541	188,344	166,433